Javascript must be enabled to continue!
AAV production and purification v1
View through CrossRef
We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and noninvasive gene transfer to the central and peripheral nervous systems. However, a detailed protocol for generating and systemically delivering novel AAV variants was not previously available. In this protocol, we describe how to produce and intravenously administer AAVs to adult mice to specifically label and/or genetically manipulate cells in the nervous system and organs, including the heart. The procedure comprises three separate stages: AAV production, intravenous delivery, and evaluation of transgene expression. The protocol spans 8 d, excluding the time required to assess gene expression, and can be readily adopted by researchers with basic molecular biology, cell culture, and animal work experience. We provide guidelines for experimental design and choice of the capsid, cargo, and viral dose appropriate for the experimental aims. The procedures outlined here are adaptable to diverse biomedical applications, from anatomical and functional mapping to gene expression, silencing, and editing. *IMPORTANT* This protocol is based on Challis et al., Nat Protoc 14: 379, published in 2019. Since that publication, we have made a number of modifications to the protocol to increase throughput or yield. With these modifications, we routinely achieve yields of >5e12 vg per 150 cm dish, with a well packaging capsid (e.g. AAV9, AAV-PHP.eB, and AAV.CAP-B10). In Challis et al., Nat Protoc 14: 379, a Type 70 Ti rotor is used for ultracentrifugation of the AAV through a density gradient (steps 32-36). This rotor can hold 8 tubes, allowing for simultaneous purification of 8 separate AAV variants, at 1-10 plates (150 mm plates) per variant. To increase throughput, we also provide a smaller scale purification workflow with a Type 70.1 Ti rotor, which can allow for purification of 12 separate AAV variants, at 1-3 plates (150 mm plates) per variant. Significant modifications to the referenced protocol are indicated by *MODIFICATION*. Read and understand the original protocol, before following a modified protocol. Following the original protocol should also yield expected results.
Title: AAV production and purification v1
Description:
We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and noninvasive gene transfer to the central and peripheral nervous systems.
However, a detailed protocol for generating and systemically delivering novel AAV variants was not previously available.
In this protocol, we describe how to produce and intravenously administer AAVs to adult mice to specifically label and/or genetically manipulate cells in the nervous system and organs, including the heart.
The procedure comprises three separate stages: AAV production, intravenous delivery, and evaluation of transgene expression.
The protocol spans 8 d, excluding the time required to assess gene expression, and can be readily adopted by researchers with basic molecular biology, cell culture, and animal work experience.
We provide guidelines for experimental design and choice of the capsid, cargo, and viral dose appropriate for the experimental aims.
The procedures outlined here are adaptable to diverse biomedical applications, from anatomical and functional mapping to gene expression, silencing, and editing.
*IMPORTANT* This protocol is based on Challis et al.
, Nat Protoc 14: 379, published in 2019.
Since that publication, we have made a number of modifications to the protocol to increase throughput or yield.
With these modifications, we routinely achieve yields of >5e12 vg per 150 cm dish, with a well packaging capsid (e.
g.
AAV9, AAV-PHP.
eB, and AAV.
CAP-B10).
In Challis et al.
, Nat Protoc 14: 379, a Type 70 Ti rotor is used for ultracentrifugation of the AAV through a density gradient (steps 32-36).
This rotor can hold 8 tubes, allowing for simultaneous purification of 8 separate AAV variants, at 1-10 plates (150 mm plates) per variant.
To increase throughput, we also provide a smaller scale purification workflow with a Type 70.
1 Ti rotor, which can allow for purification of 12 separate AAV variants, at 1-3 plates (150 mm plates) per variant.
Significant modifications to the referenced protocol are indicated by *MODIFICATION*.
Read and understand the original protocol, before following a modified protocol.
Following the original protocol should also yield expected results.
Related Results
The Use of Adeno-associated virus (AAV) in Vaccine Development
The Use of Adeno-associated virus (AAV) in Vaccine Development
Adeno-associated virus (AAV) is a very tiny (20-26 nm) icosahedral and non-enveloped virus, and it belongs to the Parvoviridae family. AAV vectors are the most widely used ...
Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia
Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia
Abstract
Objective: This study aimed to investigate the inhibitory effect of CTLA4-Ig on anti-AAV neutralizing antibody ...
AAV production and purification v1
AAV production and purification v1
We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and noninvasive gene transfer to the central and peripheral nervous systems. However, a detailed ...
Adeno‐associated Viral Vectors in Gene Therapy
Adeno‐associated Viral Vectors in Gene Therapy
Abstract
Recombinant vectors based on a nonpathogenic human parvovirus, the
adeno‐associated virus
(A...
A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors
A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors
IntroductionUse of adeno-associated virus (AAV) vectors is complicated by host immune responses that can limit transgene expression. Recent clinical trials using AAV vectors to del...
Élimination des vapeurs toxiques par oxydation : développement de procédures d'évaluation des systèmes de purification de l'air des conduits de ventilation
Élimination des vapeurs toxiques par oxydation : développement de procédures d'évaluation des systèmes de purification de l'air des conduits de ventilation
L'exposition à des composés organiques volatils (COV) dans les lieux de travail peut avoir des effets aigus, notamment sous forme d'irritation de la peau, des yeux, de la bouche et...
MO038ANTIMYELOPEROXIDASE AND PROTEINASE 3 ANTIBODIES ARE A USEFUL MARKER AS NEPHRITIS FLARE PREDICTOR IN ANCA-ASSOCIATED VASCULITIS
MO038ANTIMYELOPEROXIDASE AND PROTEINASE 3 ANTIBODIES ARE A USEFUL MARKER AS NEPHRITIS FLARE PREDICTOR IN ANCA-ASSOCIATED VASCULITIS
Abstract
Background and Aims
The diagnostic utility of ANCA antibodies in ANCA associated-vasculitis (AAV), antiproteinase 3 (PR...
AAV-Mediated CAR-T therapy eradicate HIV reservoirs with augmented safety and persistence
AAV-Mediated CAR-T therapy eradicate HIV reservoirs with augmented safety and persistence
Abstract
HIV-1 persists in latent reservoirs within CD4 cells, posing a major barrier to cure. Chimeric antigen receptor (CAR) T-cell therapy has shown promise against ...

